EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review

Mudassir M Wani, Mohammad I Sheikh, Tahir Bhat, Zubair Bhat, Arshad Bhat

Current Urology · 2021-09 · 15 (3) · 153-160

DOI: 10.1097/cu9.0000000000000037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Urology, online erschienen am 17.08.2021. Verfasst von Mudassir M Wani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Glangwili General Hospital, Carmarthen, Wales, UK. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. Materials and methods: A literature review was carried out, using key words in different databases including MEDLINE, PUBMED, and EMBASE. All relevant published articles during last 5 years with full texts available were included in this review for critical analysis and evaluation. In total, there were 20 studies including 7 systemic reviews, 6 retrospective cohort, 3 prospective cohort, 2 randomized controlled trials, and 2 cross sectional studies.

Results

After critical evaluation the results were considered under parameters of efficacy, adverse effects, adherence and persistence, tolerability, cost-effectiveness. In 9 studies efficacy was evaluated, 5 studies dealt with adverse effects, same number evaluated adherence and persistence. Cost effectiveness was compared in 3 and same number of studies also compared tolerability.

Conclusions

To conclude, we found mirabegron is as efficacious as any other antimuscarnics, has better tolerability (including elderly), has better adverse effect profile, is cost effective, has better persistence and adherence rates at 12 months.

Schlagwörter

Stichwörter der Autor:innen

AntimuscarnicsBeta-adrenergic agonistsMirabegronOveractive bladder

Autor:innen und Institutionen

  • Department of Urology, Glangwili General Hospital, Carmarthen, Wales, UK.
  • Department of Urology, Medway Maritime Hospital, Gillingham, Kent, UK.
  • Department of Urology, Hereford County Hospital, Hereford, Herefordshire, UK.

Zitieren

APA

Wani, M. M., Sheikh, M. I., Bhat, T., Bhat, Z., & Bhat, A. (2021). Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review. Current Urology, 15(3), 153-160. https://doi.org/10.1097/cu9.0000000000000037

Vancouver

Wani MM, Sheikh MI, Bhat T, Bhat Z, Bhat A. Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review. Current Urology. 2021;15(3):153-160. doi:10.1097/cu9.0000000000000037

BibTeX
@article{Wani2021,
  author = {Wani, Mudassir M and Sheikh, Mohammad I and Bhat, Tahir and Bhat, Zubair and Bhat, Arshad},
  title = {Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review},
  journal = {Current Urology},
  year = {2021},
  volume = {15},
  number = {3},
  pages = {153--160},
  doi = {10.1097/cu9.0000000000000037}
}
Kostenlos starten →